Clinical Trial of Intranasal Delivery of NT-301
NCT06954428 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 49
Last updated 2026-02-19
Summary
The purpose of this research project is to investigate the safety and tolerability of an approved drug (Apomorphine) when administered as a nasal powder spray formulation (NT-301) as well as collect information on how NT-301 moves into, through and out of your body, called Pharmacokinetics. The study also aims to compare the safety, tolerability and pharmacokinetics of NT-301 to an injectable Apomorphine product (Movapo Pen), already approved for use in Australia.
Conditions
- Tolerability of NT-301 Nasal Spray
- Pharmacokinetics of NT-301 Nasal Spray
- Safety of NT-301 Nasal Spray
- Performance of NT-301 Nasal Spray Device
Interventions
- COMBINATION_PRODUCT
-
NT-301 1 mg
unidose of 1 mg apomorphine through nasal spray
- COMBINATION_PRODUCT
-
NT-301 2 mg
unidose of 2 mg apomorphine through nasal spray
- COMBINATION_PRODUCT
-
Placebo 1 mg
Matching Placebo to NT-301 1 mg
- COMBINATION_PRODUCT
-
Placebo 2 mg
Matching Placebo to NT-301 2 mg
- COMBINATION_PRODUCT
-
Placebo 3 mg
Matching Placebo to NT-301 3 mg
- COMBINATION_PRODUCT
-
NT-301 3 mg
unidose apomorphine nasal spray 3 mg
- COMBINATION_PRODUCT
-
NT-301 4 mg
unidose apomorphine nasal spray 4 mg
- COMBINATION_PRODUCT
-
Placebo 4 mg
Matching placebo to NT-301 4 mg
- DRUG
-
Active Comparator: Movapo pen
Approved drug in Australia
- DRUG
-
Experimental: BA NT-301 strength 4 mg
Combination Product: NT-301 apomorphine nasal spray strength 4 mg given by 2 mg on each nostril (2x2 mg)
Sponsors & Collaborators
-
CMAX Clinical Research Pty Limited
collaborator UNKNOWN -
Beyond Drug Development
collaborator UNKNOWN -
Nano PharmaSolutions Australia
lead INDUSTRY
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- TRIPLE
- Model
- SEQUENTIAL
Eligibility
- Min Age
- 18 Years
- Max Age
- 60 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2025-06-20
- Primary Completion
- 2025-12-12
- Completion
- 2025-12-12
- FDA Drug
- Yes
- FDA Device
- Yes
Countries
- Australia
Study Locations
More Related Trials
-
A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ABT-384 in Elderly Subjects
NCT00968422 ·Status: COMPLETED ·Phase: PHASE1
-
Pharmacokinetics & Tolerability Study of MAP0004 in Smoking and Non-Smoking Adult Volunteers
NCT01199965 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Safety and Pharmacokinetics of NP10679 in Normal Healthy Volunteers
NCT03565861 ·Status: COMPLETED ·Phase: PHASE1
-
A Multiple Dose Pharmacokinetic Study of Perampanel in Korean Healthy Subjects
NCT02020486 ·Status: COMPLETED ·Phase: PHASE1
-
A Safety, Tolerability and Pharmacokinetic Study of ABT-102 in Healthy Subjects
NCT00854659 ·Status: COMPLETED ·Phase: PHASE1
-
A Phase 1, Single-Dose Safety and Pharmacokinetic Study of Sodium ST20 in Healthy Volunteers
NCT00614016 ·Status: COMPLETED ·Phase: PHASE1
-
Pharmacokinetics and Safety of POL7080 in Patients With Renal Impairment
NCT02110459 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of BCX17725
NCT06539507 ·Status: RECRUITING ·Phase: PHASE1
-
A Study Evaluating the Pharmacokinetics and Relative Bioavailability of Emraclidine Immediate-Release Tablets in Healthy Adult Participants
NCT05933187 ·Status: COMPLETED ·Phase: PHASE1
-
AMAP102 - Safety, Tolerability and Pharmacokinetics in Healthy Subjects
NCT00995605 ·Status: TERMINATED ·Phase: PHASE1
-
Study to Investigate the Pharmacodynamics, Pharmacokinetics and Safety of a Single Oral Repeated Dose of 500 mg Nicotinic Acid as Tablets in Healthy Subjects
NCT01258491 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015 and Co-administration of BR1015-3 and BR1015-2 Under Fed Conditions
NCT06744439 ·Status: COMPLETED ·Phase: PHASE1
-
The Food Effect on Pharmacokinetics of DA-8010 After a Single Administration of DA-8010 2.5 mg or 5 mg in Healthy Subjects
NCT04686825 ·Status: COMPLETED ·Phase: PHASE1
-
Pharmacokinetics (Drug Levels in Blood) of BMS-986165 When Taken as Various Solid Tablet Prototypes by Healthy Participants
NCT04249284 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Assess the Effect of AZD5055 on the Pharmacokinetics (PK) of Nintedanib in Healthy Participants.
NCT05644600 ·Status: TERMINATED ·Phase: PHASE1
-
Comparative Pharmacokinetic Study of Aprepitant Injection in Humans
NCT06226506 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1
-
Safety, Pharmacodynamics, and Pharmacokinetics of Different Dosing Regimens of MK-8266 in Participants With Hypertension (MK-8266-008)
NCT01244035 ·Status: COMPLETED ·Phase: PHASE1
-
Safety and Pharmacokinetics Study of BCD101 in Healthy Volunteers
NCT07282145 ·Status: RECRUITING ·Phase: PHASE1
-
A Study to Evaluate Novel KarX and KarT Prototypes Versus the KarXT and KarX-EC Reference Following Single Doses, Explore the Effect of Food After Multiple Doses of Selected Prototypes, and Evaluate Alternative Formulations of KarX and KarXT Following Single and Multiple Ascending Doses
NCT07063342 ·Status: RECRUITING ·Phase: PHASE1
-
Effect of Hepatic Impairment on the Pharmacokinetics of a Single Dose of TD-9855
NCT04200573 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Assess the Adverse Events and How Oral Emraclidine Moves Through the Body of Healthy Elderly Adult Participants
NCT07219030 ·Status: RECRUITING ·Phase: PHASE1
-
A Phase 1 Study Investigating the Safety and Pharmacokinetics of Repeat-dose Intravenous Infusion of MTP-131 in Subjects With Impaired Renal Function
NCT02436447 ·Status: COMPLETED ·Phase: PHASE1
-
Study to Investigate the Pharmacokinetics, Safety, and Tolerability of BMT101 in Healthy Male Volunteers
NCT03133130 ·Status: COMPLETED ·Phase: PHASE1
-
Study to Determine the Tolerability, Safety and Pharmacokinetics of Ketorolac Tromethamine by Intranasal Administration in Healthy Volunteers
NCT01363050 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Evaluate the Pharmacokinetics and Safety of DBPR108 in Subjects With Hepatic Impairment
NCT04859426 ·Status: COMPLETED ·Phase: PHASE1